• Topical pain relief

Zingo Generic Name & Formulations

General Description

Lidocaine HCl (as monohydrate) 0.5mg/device; pwd for intradermal inj.

Pharmacological Class

Local anesthetic (amide-type).

How Supplied

Single-use device (disposable, needle-free)—12


Generic Availability


Zingo Indications


To provide local analgesia prior to venipuncture in adults and children or peripheral IV cannulation in children.

Zingo Dosage and Administration

Adults and Children

<3yrs: not established. ≥3yrs: Use only on intact skin. Apply one 0.5mg dose to the planned procedure site 1–3 mins before needle insertion; may repeat once at new site after initial attempt failed. Multiple administrations to same site: not recommended.

Zingo Contraindications

Not Applicable

Zingo Boxed Warnings

Not Applicable

Zingo Warnings/Precautions


Avoid eyes, body orifices, mucous membranes or areas with a compromised skin barrier. Severe hepatic disease or pseudocholinesterase deficiency. Bleeding tendencies or platelet disorders: higher risk of superficial dermal bleeding. Risk of methemoglobinemia (esp. in G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants <6 months of age, concurrent exposure to oxidizing agents or metabolites); monitor. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.

Zingo Pharmacokinetics

See Literature

Zingo Interactions


Increased risk of methemoglobinemia when concurrently exposed to nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, others.

Zingo Adverse Reactions

Adverse Reactions

Application-site reactions (eg, erythema, petechiae, edema, pruritus), systemic reactions (eg, nausea, vomiting), dizziness.

Zingo Clinical Trials

See Literature

Zingo Note

Not Applicable

Zingo Patient Counseling

See Literature